MENSHealthcare · BiotechnologyMENS Stock Forecast: Jyong Biotech Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 1 Aug 2026 — in the weakest quartile.
MENS stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Jyong Biotech Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (70): Smaller than most of the companies we track.
Volatility (5): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Jyong Biotech Ltd. — and when they’d sell — is the membership.
MENS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MENS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MENS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Jyong Biotech Ltd. (MENS) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- −70.6×
Cheaper than 95% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 18.8%
- Return on assets
- −12.0%
- Dividend yield
- —
Higher than 80% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MENS vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MENS appears on the weeks it earns a place.
Frequently asked questions about MENS stock
How does Ticker Nerd's model rank MENS?
As at 1 Aug 2026, Jyong Biotech Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).
What is the MENS stock forecast for 2030?
No analyst covering Jyong Biotech Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MENS are extrapolating price history, which says nothing about the business.
How has MENS stock performed over the past year?
Jyong Biotech Ltd. returned -89.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Jyong Biotech Ltd. do?
Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived pharmaceuticals.
About Jyong Biotech Ltd.
Jyong Biotech Ltd. is a biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived pharmaceuticals. Established in 2002, the company specializes in addressing urinary system diseases, targeting markets in the United States, European Union, and Asia, with a particular emphasis on Taiwan and mainland China. Jyong Biotech’s pipeline includes drug candidates for conditions such as benign prostate hyperplasia, lower urinary tract symptoms, prostate cancer prevention, and interstitial cystitis. Notably, its lead candidate MCS-2 has been submitted for regulatory approval in the United States. The company’s vertically integrated model spans early-stage drug discovery, clinical development, regulatory affairs, manufacturing, and commercialization. Through its proprietary R&D platform, Jyong Biotech aims to deliver safe, effective, and differentiated botanical therapies, playing a distinctive role in advancing treatments for urological disorders and meeting unmet medical needs in global healthcare markets.
CEO Ms. Fu-Feng Kuo · 27 employees · Taiwan · https://jyongbio.com